Market
Rivermark pockets $20m in Series D for late-stage prostate device trial
Rivermark Medical raised $20 million in Series D funding to advance its pivotal trial for FloStent, a device designed to treat benign prostatic hyperplasia. The capital will support late-stage clinical development of the minimally invasive urology device.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network